Rulin C Hechter1, Lei Qian2, Yi Luo3, Deborah S Ling Grant4, Roger Baxter5, Nicola P Klein6, Karen Valdez Nunley7, Laurie Aukes8, Cosmina Hogea9, Girishanthy Krishnarajah10, Brandon J Patterson11, Theresa M Im12, Hung Fu Tseng13. 1. Kaiser Permanente Southern California, 100 S. Los Robles, 2nd Floor, Pasadena, CA 91101, USA. Electronic address: Rulin.C.Hechter@kp.org. 2. Kaiser Permanente Southern California, 100 S. Los Robles, 2nd Floor, Pasadena, CA 91101, USA. Electronic address: Lei.X.Qian@kp.org. 3. Kaiser Permanente Southern California, 100 S. Los Robles, 2nd Floor, Pasadena, CA 91101, USA. Electronic address: Yi.X.Luo@kp.org. 4. Kaiser Permanente Southern California, 100 S. Los Robles, 2nd Floor, Pasadena, CA 91101, USA. Electronic address: Deborah.S.Ling-Grant@kp.org. 5. Kaiser Permanente Northern California, 1 Kaiser Plaza, 16th Floor, Oakland, CA 94612, USA. 6. Kaiser Permanente Northern California, 1 Kaiser Plaza, 16th Floor, Oakland, CA 94612, USA. Electronic address: nicola.klein@kp.org. 7. Kaiser Permanente Northern California, 1 Kaiser Plaza, 16th Floor, Oakland, CA 94612, USA. Electronic address: Karen.V.Nunley@kp.org. 8. Kaiser Permanente Northern California, 1 Kaiser Plaza, 16th Floor, Oakland, CA 94612, USA. Electronic address: Laurie.A.Aukes@kp.org. 9. GSK, 5 Crescent Drive, Philadelphia, PA 19112, USA. Electronic address: cosmina.s.hogea@gsk.com. 10. GSK, 5 Crescent Drive, Philadelphia, PA 19112, USA. Electronic address: shanthy.krishnarajah@cslbehring.com. 11. GSK, 5 Crescent Drive, Philadelphia, PA 19112, USA. Electronic address: brandon.j.patterson@gsk.com. 12. Kaiser Permanente Southern California, 100 S. Los Robles, 2nd Floor, Pasadena, CA 91101, USA. Electronic address: theresa.m.im@kp.org. 13. Kaiser Permanente Southern California, 100 S. Los Robles, 2nd Floor, Pasadena, CA 91101, USA. Electronic address: Hung-Fu.X.Tseng@kp.org.
Abstract
OBJECTIVE: The Advisory Committee on Immunization Practices recommends Hepatitis B (HepB) vaccine for previously unvaccinated adults <60 years with diabetes mellitus. This observational retrospective cohort study assessed the impact of implementing electronic provider reminders on HepB vaccine initiation and 3-dose series completion rates among insured adults with diabetes aged 19-59 years old. RESEARCH DESIGN AND METHODS: Difference-in-difference (DID) analyses compared changes in vaccine initiation and completion rates (ratio of the rate ratio [RRR] and 95% confidence interval [CI]) during 12 months pre- and post-implementation between intervention and control sites. We examined trends in vaccine initiation and completion rates by plotting monthly rates during the study period. We also calculated the overall HepB vaccine coverage rates with 95% CI among all adults with diabetes aged 19-59 years old at the start and end date of the study period. RESULTS: Baseline HepB vaccine initiation and completion rates were similar at both the intervention and control sites. Gender, age, and race/ethnicity distributions within both sites were similar during the 12 months pre- and post-implementation. DID analyses demonstrated statistically significant differences in the changes of the annual vaccine initiation rates (RRR: 70.7, 95% CI: 62.8-79.6) and the third dose completion rates (RRR = 18.7, 95% CI: 14.2-24.8) between the two sites. The coverage increased significantly at the intervention site while it remained low at the control site. CONCLUSIONS: Use of provider reminders is highly effective in increasing both HepB vaccine initiation and series completion rates among adults with diabetes.
OBJECTIVE: The Advisory Committee on Immunization Practices recommends Hepatitis B (HepB) vaccine for previously unvaccinated adults <60 years with diabetes mellitus. This observational retrospective cohort study assessed the impact of implementing electronic provider reminders on HepB vaccine initiation and 3-dose series completion rates among insured adults with diabetes aged 19-59 years old. RESEARCH DESIGN AND METHODS: Difference-in-difference (DID) analyses compared changes in vaccine initiation and completion rates (ratio of the rate ratio [RRR] and 95% confidence interval [CI]) during 12 months pre- and post-implementation between intervention and control sites. We examined trends in vaccine initiation and completion rates by plotting monthly rates during the study period. We also calculated the overall HepB vaccine coverage rates with 95% CI among all adults with diabetes aged 19-59 years old at the start and end date of the study period. RESULTS: Baseline HepB vaccine initiation and completion rates were similar at both the intervention and control sites. Gender, age, and race/ethnicity distributions within both sites were similar during the 12 months pre- and post-implementation. DID analyses demonstrated statistically significant differences in the changes of the annual vaccine initiation rates (RRR: 70.7, 95% CI: 62.8-79.6) and the third dose completion rates (RRR = 18.7, 95% CI: 14.2-24.8) between the two sites. The coverage increased significantly at the intervention site while it remained low at the control site. CONCLUSIONS: Use of provider reminders is highly effective in increasing both HepB vaccine initiation and series completion rates among adults with diabetes.
Authors: Katia Bruxvoort; Jeff Slezak; Runxin Huang; Bradley Ackerson; Lina S Sy; Lei Qian; Kristi Reynolds; William Towner; Zendi Solano; Cheryl Mercado; Randall Hyer; Robert Janssen; Steven J Jacobsen Journal: JAMA Netw Open Date: 2020-11-02
Authors: Timo Vesikari; Adam Finn; Pierre van Damme; Isabel Leroux-Roels; Geert Leroux-Roels; Nathan Segall; Azhar Toma; Gerald Vallieres; Ronnie Aronson; Dennis Reich; Samir Arora; Peter J Ruane; Clancy L Cone; Michael Manns; Catherine Cosgrove; Saul N Faust; Maheshi N Ramasamy; Nathalie Machluf; Johanna N Spaans; Bebi Yassin-Rajkumar; David Anderson; Vlad Popovic; Francisco Diaz-Mitoma Journal: JAMA Netw Open Date: 2021-10-01
Authors: Stanley Xu; Vennis Hong; Lina S Sy; Sungching C Glenn; Denison S Ryan; Kerresa L Morrissette; Jennifer C Nelson; Simon J Hambidge; Bradley Crane; Ousseny Zerbo; Malini B DeSilva; Jason M Glanz; James G Donahue; Elizabeth Liles; Jonathan Duffy; Lei Qian Journal: Vaccine Date: 2022-04-18 Impact factor: 4.169